Michael J. Tomsicek

2020 - CRISPR Therapeutics AG

In 2020, Michael J. Tomsicek earned a total compensation of $2.6M as Chief Financial Officer at CRISPR Therapeutics AG, a 35% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$244,760
Option Awards$1,563,531
Salary$422,000
Stock Awards$379,695
Other$11,400
Total$2,621,386

Tomsicek received $1.6M in option awards, accounting for 60% of the total pay in 2020.

Tomsicek also received $244.8K in non-equity incentive plan, $422K in salary, $379.7K in stock awards and $11.4K in other compensation.

Rankings

In 2020, Michael J. Tomsicek's compensation ranked 4,365th out of 13,090 executives tracked by ExecPay. In other words, Tomsicek earned more than 66.7% of executives.

ClassificationRankingPercentile
All
4,365
out of 13,090
67th
Division
Manufacturing
1,770
out of 5,618
69th
Major group
Chemicals And Allied Products
693
out of 2,251
69th
Industry group
Drugs
593
out of 1,951
70th
Industry
Biological Products, Except Diagnostic Substances
137
out of 411
67th
Source: SEC filing on April 28, 2021.

Tomsicek's colleagues

We found four more compensation records of executives who worked with Michael J. Tomsicek at CRISPR Therapeutics AG in 2020.

2020

Samarth Kulkarni

CRISPR Therapeutics AG

Chief Executive Officer

2020

Tony Ho

CRISPR Therapeutics AG

EVP, Research and Development

2020

Lawrence Klein

CRISPR Therapeutics AG

Chief Operating Officer

2020

James Kasinger

CRISPR Therapeutics AG

General Counsel

News

In-depth

You may also like